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Angelika Amon obtained her PhD in 
1994 from the University of Vienna for 
her work on the molecular mechanisms 
governing cell cycle progression in 
budding yeast. She then joined the 
laboratory of Dr. Ruth Lehmann at the 
Whitehead Institute to investigate germ 
cell formation in Drosophila. In 1996 
Angelika accepted a Whitehead Fellow 
position to study the mechanisms 
governing chromosome segregation 
and exit from mitosis. Angelika joined 
the faculty of the Department of Biology 
and the Koch Institute for Integrative 
Cancer Research at MIT in 1999 and 
the Howard Hughes Medical Institute 
in 2000. At the Koch Institute she 
studies the molecular mechanisms that 
prevent chromosome mis-segregation 
during mitosis and meiosis and the 
consequences when these mechanisms 
fail and cells become aneuploid.
How did you get into biology? I guess 
my story is that of most scientists. I 
cannot recall a time when I did NOT 
want to be a biologist. As a child I 
wanted to be a dinosaur scientist, 
then a zoologist. In high school I 
was introduced to molecular and cell 
biology and I knew that this is what I 
wanted to do. I very vividly recall seeing 
these black and white movies showing 
cell division and I though that cells were 
the coolest things ever. I then knew that 
I wanted to be a geneticist/molecular 
biologist, studying the inner working of 
cells and decided to major in genetics 
at the University of Vienna in Austria. 
How to do science I learned during 
my master’s and PhD thesis work. I 
worked in Kim Nasmyth’s lab at the 
Institute of Molecular Pathology (IMP) 
in Vienna and he (personally) taught 
me the ins and outs of yeast genetics 
and molecular biology and how to 
do science in general. This was an 
immensely defining experience. He was 
a tough teacher but I learned a lot.
What did you do next? After my PhD 
I went to Ruth Lehmann’s laboratory 
to study germ cell development in 
Drosophila. Gustav Ammerer first 
mentioned Ruth’s work to me. After 
reading her papers I was so impressed 
by the elegant genetic approach she 
took to solve fundamental biological problems that I wanted to work with 
her. I was lucky that she accepted me 
into her lab and so in 1994 I moved to 
the Whitehead Institute. The transition 
was not easy, I must say. It took a while 
to get used to the US lifestyle but I love 
it here now. 
In 1995 Ruth decided to move to 
New York, but I was not able to move 
with her. At the same time I realized 
that flies were not for me. Although the 
genetics is beautiful, the experimental 
repertoire available at the time was 
limited. Budding yeast, which I worked 
with as a graduate student, spoils you. 
When you work with yeast, your brain is 
the rate-limiting factor. You can do any 
experiment. You can address any basic 
cell biological question without the 
tools and technology limiting you.
So at the time I was at a loss and 
really did not know what to do. But then 
the best opportunity of my professional 
life arose. Terry Orr-Weaver and 
Rick Young asked me whether I was 
interested in becoming a Whitehead 
Fellow. At the time not many research 
institutions had such programs. The 
Whitehead Fellow’s program offers 
young people usually straight out of 
graduate school the possibility to 
work independently. The Whitehead 
guarantees the Fellows’ salary, not 
to mention a technician’s salary and 
supplies, and allows the freedom to do 
whatever you want to. 
This was a tremendous opportunity. It 
was a chance to be independent at an 
early stage of my career. I should add 
that it was also a daunting challenge. 
I was nervous that I was not ready but 
in the end decided to take the plunge. 
In hindsight this was the third-best 
decision of my life.  Doing science 
without the burden of raising money or 
teaching was just wonderful. I also had 
the great fortune of working with two 
highly talented women, Rosella Visintin 
and Susanne Prinz. We had so much 
fun doing science together, exploring 
new biology and making exciting 
discoveries. These years were the best 
time of my scientific life.
I also want to make a point here 
that is very dear to my heart. PhDs 
and postdocs take longer and 
longer. Nowadays it is not unusual 
for budding scientists to spend 5–6 
years conducting their PhD studies 
and similar amounts of time in their 
postdocs. This means that scientists 
are in their mid-thirties when they 
start their careers. Of course, securing 
a tenure-track position is only the beginning. At this point you have only 
just gotten the opportunity to start your 
own research program and this is when 
the real race starts — the tenure clock 
starts ticking. This ticking, of course, 
coincides with another ticking — that of 
the biological clock, which is especially 
hard for women who would like to have 
children and a career in science. 
Because I was a fellow, I was 
independent earlier and, importantly, 
could start my research program 
without the burden of having to obtain 
funding for my research, without having 
to teach and without all the other 
stresses associated with the run-up to 
tenure. This early independence and 
hence longer tenure clock also made 
it easier to have children and start my 
research program at the same time. 
I really wish that there were more 
opportunities for young scientists to 
ease into independence and start their 
careers without all the pressures that 
I just mentioned. It would allow young 
people to be adventurous, to think 
outside the box and try something risky.
Have you ever considered going 
back to Europe? I have. I miss my 
family, but I also really like working at 
MIT and living in Boston. I have had 
opportunities at MIT and in the US in 
general that I would not have had in 
Europe. What is so special about the 
US academic structure is that it gives 
young people the opportunity to do 
independent research, though as I 
mentioned above, the ‘young’ get older 
and older. 
However, I fear that this very reason 
for the tremendous success of science 
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What are they? Burying beetles are 
members of the coleopteran family 
Silphidae (the carrion beetles) of 
the genus Nicrophorus. There are 
approximately 75 species in this 
Northern hemisphere genus. As 
for most other silphids, the use of 
vertebrate carrion is an essential part 
of a burying beetles life. But unlike 
other silphids, which use carrion 
primarily as an adult food source or 
somewhere to lay eggs, Nicrophorus 
beetles bury the carcasses. This 
‘grave-digging’ behaviour gives them 
their common English name: Sexton 
beetles.
Why do they bury carcasses? This 
behaviour has long been a source 
of fascination for naturalists. The 
flamboyant 19th century entomologist 
Jean-Henri Fabre, for example, 
devoted two chapters of his book 
The Wonders of Instinct to burying 
beetles: “The burying beetle...so 
different from the cadaveric mob in 
dress and habits.....across his wing-
cases he wears a double, scalloped 
scarf of vermilion. An elegant, almost 
sumptuous costume....as befits your 
undertaker’s man.” The burying 
beetles aren’t laying the bodies 
to rest though; instead, as Fabre 
explained, “he buries it in order to 
establish his progeny therein.”
So the carcasses are nurseries for 
rearing baby burying beetles? Yes.
But apart from 19th century 
naturalists who cares about 
burying beetles? Burying beetles 
have an important role as nutrient 
recyclers in ecosystems and forensic 
pathologists like to find some 
species in corpses because they are 
bio-indicators of time of death, but 
it is behavioural and evolutionary 
ecologists that care most about 
burying beetles. Apart from other 
burying beetles that is.
Why is that then? In addition to 
being particularly well-dressed 
Quick guideextraordinary financial pressures that the NIH currently experience threatens 
the US science enterprise. This not only 
puts extreme pressure on established 
scientists but makes it very difficult for 
young people to develop their research 
programs. The NIH have put in place 
mechanisms to make it easier for young 
people to obtain their first grant, but 
all this does is get new researchers 
through the first four years of their 
careers. Renewing this first grant is 
extremely difficult. Young scientists 
must compete with the entire scientific 
community for an extremely limited 
amount of resources. 
Unfortunately, there are only two 
solutions to this problem: putting more 
money into research or shrinking the 
research enterprise. At the moment 
the US government is pursuing the 
latter. The result is trivial to forecast. 
The US science enterprise will shrink 
dramatically, while at the same time 
countries like India and China who 
heavily invest in research will become 
the world’s science and technology 
leaders. It seems to me that every 
American, Democrat or Republican, 
should be concerned about this and 
make it their highest priority and that 
of their elected officials to maintain 
the US’s leadership position in science 
and technology development. Saving 
a buck or two by cutting the budgets 
of funding agencies such as the NIH 
or NSF (the NIH’s and NSF’s research 
budgets are small change compared 
to other budget items; e.g. defense) is 
really short sighted and, importantly, the 
impact is long term. Firstly, people with 
career aspirations in science are going 
to be pruned. The days of pruning 
come when study sections meet — 
either for the first grant or the first 
renewal — and then when university 
promotion committees meet, by which 
time the aspiring scientist is 35+ and in 
need of a new career. Secondly, seeing 
established and starting scientists alike 
struggle so much to secure funding and 
make a living as scientists will turn off 
the coming generations from research.
What kind of research should we 
be funding? I firmly believe that real 
medical breakthroughs come out 
of basic research. This is why we 
must make funding basic research 
a priority. As we mostly rely on tax 
dollars to conduct this research it is 
our responsibility to explain to the 
public how basic research leads to 
new medical treatments. We must explain that not every research 
project will lead to the development 
of a new medicine and that we cannot 
predict where the next breakthrough 
in science will come from. We must 
further make it clear to the public and 
lawmakers alike that to ensure that 
breakthroughs continue to occur, we 
must keep funding a broad range of 
basic research at a healthy level and 
accept that not every discovery will 
have an immediate impact on our lives. 
Alexander Fleming did not wake up one 
morning and decide to save human 
kind from bacterial infections. He 
made an accidental discovery (whose 
importance he realized) that basically 
allowed humans to escape natural 
selection. This was no small feat and 
arguably the most important medical 
breakthrough of all time.
What are you hoping to accomplish 
in the next few years? My lab has a 
long-standing interest in the cell cycle. 
We study the mechanisms that ensure 
that chromosomes are segregated 
accurately and what happens to 
cells in which these mechanisms 
fail, causing them to become 
aneuploid. While over the years we 
have obtained a reasonably detailed 
understanding of the mechanisms 
governing chromosome segregation 
we are only beginning to understand 
how aneuploidy impacts cell and 
organismal physiology. Understanding 
the complex impact of changing the 
dosage of hundreds if not thousands 
of genes at once is challenging, but 
exciting. Aneuploidy’s impact on 
human health — it is associated with 
cancer and causes miscarriages and 
developmental defects — is also a 
question we are very interested in.  
Answering these questions will keep us 
busy for years to come. 
But I am also always looking for new 
challenges. In fact, I make an effort to 
start a new research project every five 
years or so. So in this spirit we have 
recently begun to study mitochondria 
and how they communicate with 
the nucleus. I like a good mystery 
and it seems to me that there is a 
lot to be learned there, both from 
a cell biological and evolutionary 
perspective.
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